-
Rituximab, sold
under the
brand name
Rituxan among others, is a
monoclonal antibody medication used to
treat certain autoimmune diseases and
types of...
- of t-FL (e.g. the
addition to
standard chemotherapy of
agents such as
rituximab) have
improved overall survival times.
These newer regimens may also delay...
-
patients who
cannot use corticosteroids. The anti-CD20
monoclonal antibody rituximab has been
found to be
effective in
treating some
otherwise refractory cases...
-
immunotherapy (i.e.
rituximab, or a
combination (e.g.
chlorambucil +
rituximab or
fludarabine +
rituximab or
bendamustine +
rituximab)
immunotherapy plus...
-
antibodies such as
rituximab,
which are
increasingly being used as first-line treatment. In
summer 2018, the FDA
granted full
approval to
rituximab for this application...
-
methotrexate for
moderate to
severe rheumatoid arthritis. The
biologic agent rituximab (anti-B cell therapy) is now
licensed for use in
refractory rheumatoid...
- as
rituximab or
cyclophosphamide and high-dose
corticosteroids to
control the
symptoms of the
disease and azathioprine, methotrexate, or
rituximab to...
-
follitropin alfa, infliximab,
insulin aspart,
insulin glargine, pegfilgrastim,
rituximab, teriparatide, and trastuzumab. A
research article about "Maximizing the...
- corticosteroids.
Sometimes the
chimeric anti-CD20
monoclonal antibody,
rituximab, is
added to this
treatment regimen to form the R-CHOP regimen. R-miniCHOP...
- multicenter, open-label
trial of
venetoclax with
rituximab (VEN+R)
versus bendamustine with
rituximab (B+R) in 389 parti****nts with CLL who had received...
